Discover Vor BiopharmaVor Biopharma Inc.'s potential with telitacicept amid funding challenges and market risks. Click for ...
The European Financial Reporting Advisory Group (EFRAG) on December 3, 2025 submitted its long-anticipated technical advice ...
Wave Life Sciences Ltd. ( WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity December 8, 2025 8:30 AM EST ...
Upstream depends on being able to display ads on our services in order to finance our journalism.
The Zimbabwe Independent on MSN
Never treat employee-engagement survey as ordinary routine exercise
employee-engagement surveys MANY organisations in Zimbabwe and elsewhere conduct employee-engagement surveys simply because it is on the annual calendar. Once the survey is completed, the results are ...
Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety ...
Photo from Freepik We make critical decisions that shape our company’s direction. Hiring. Training investments. Restructuring ...
In a timeline where the parties involved in the 23XI Racing and Front Row Motorsports v NASCAR trial couldn’t agree on ...
Dr. Natasha Bagdasarian, the state’s chief medical officer, said the rate of Michigan children ages 19-35 months receiving ...
Experts say lack of mandate staff and awareness limits NSC’s role as recommendations highlight need for autonomy better standards audit systems and improved access to official datasets ...
Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback